Gilead disclosed a partial clinical hold affecting two CAR-T cell therapy trials after several cases of ICANS, a neurotoxicity known to occur with CAR-T treatments. The hold reflects a safety review prompted by observed adverse events. The development puts additional scrutiny on trial monitoring, mitigation strategies, and dose or patient-selection criteria. For the CAR-T field, the update serves as another reminder that neurologic events continue to drive regulatory and operational changes even when overall efficacy signals are under evaluation. Companies and investigators typically respond by updating protocols and waiting for regulator clearance before resuming enrollment or dosing steps tied to the held studies.